Table 1.
EMMPRIN antibodies
| Species | EMMPRIN mAb | Binding domain | Effect on function | Reference |
|---|---|---|---|---|
| Human | MEM‐M6/6 (IgG1) | EC2 | •Altered immune synapse formation upon TCR‐mediated activation of T cells | [48], [51], [55], [56] |
| •Decreased proliferation of PBMCs and purified T cells | ||||
| •Decreased CD25, cytokine expression upon TCR‐mediated activation of T cells (no effect on tyrosine phosphorylation and IL‐2 levels) | ||||
| •Prevented pathogenic invasion (meningitis, malaria) | ||||
| 5A12 (IgG1) | EC1 | •Altered immune synapse formation upon TCR‐mediated activation of T cells | [52] | |
| •Decreased proliferation of purified T cells | ||||
| •Reduced CD25, IL‐4, tyrosine phosphorylation, calcium influx, IL‐2 levels; increased IFN‐γ | ||||
| MEM‐M6/1 (IgG1) | EC1 | •Reduced tyrosine phosphorylation levels in TCR‐stimulated T cells from SLE patients (not healthy patients) | [23], [51], [57] | |
| •Did not affect MMP activity | ||||
| •Did not inhibit T cell proliferation | ||||
| •Did not induce cell aggregation | ||||
| HI197 (IgG1) | ? | •Decreased TCR‐mediated proliferation of T cells when pre‐exposed to U937 myeloid cells before coculture | [58] | |
| MEM‐M6/8 (IgG1) | EC1 | •Induced cell aggregation and adhesion in Jurkat T cells | [23] | |
| HAb18 (IgG1) | EC1 | •Did not inhibit proliferation of purified T cells | [52], [59], [60] | |
| •Induced cell aggregation of Jurkat cells | ||||
| •Decreased CyPA‐mediated migration of Jurkat cells | ||||
| •Prevented MMP activity of fibroblasts in coculture | ||||
| M6‐1F3 (IgM) | Not EC1 nor EC2 | •Induced cell aggregation in U937 cells | [54] | |
| •Did not inhibit TCR‐mediated lymphocyte proliferation | ||||
| M6‐1B9 (IgG3) | EC1 | •Did not induce cell aggregation in U937 cells | [54] | |
| •Inhibited TCR‐mediated lymphocyte proliferation | ||||
| •Inhibited CD25 expression, IL‐2 production | ||||
| UM‐8D6 (IgG1) | EC1 | •Inhibited MMP‐9 secretion | [49], [58], [61] | |
| •Decreased T cell proliferation | ||||
| •Decreased CyPA‐mediated migration | ||||
| Mouse | RL73.2 (IgG2a) | ? | •Altered murine thymocyte development | [38], [45], [62], [61], [63], [64], [65] |
| •Decreased CyPA‐mediated migration | ||||
| •Inhibited CIA, lung inflammation, EAE, infarct size | ||||
| •Did not inhibit proliferation of MOG‐primed T cells | ||||
| •Did not inhibit the release of MMP‐9 | ||||
| Human and mouse | Clone 10 (IgM) | EC1 | •Inhibited EAE | [53], [66] |
| •Inhibited MMP‐9 secretion | ||||
| •Inhibited T cell proliferation | ||||
| •Reduced α4 integrin levels | ||||
| •Decreased T cell adhesion to endothelial cells |